Similar articles

• Different immune responses to UV-B-treated or -untreated donor spleen cells via portal vein administration.

  Yu S, Roland CR, Goss JA, Nakafusa Y, Hafenrichter D, Flye MW. Yu S, et al. Transplant Proc. 1992 Dec;24(6):2908. Transplant Proc. 1992. PMID: 1465995 No abstract available.
• Donor-specific cardiac allograft tolerance without immunosuppression after intrathymic injection of donor alloantigen.

  Goss JA, Nakafusa Y, Flye MW. Goss JA, et al. Transplant Proc. 1992 Dec;24(6):2879-80. Transplant Proc. 1992. PMID: 1465981 No abstract available.
• Prolongation of islet allografts by pretreatment with intrathymic UV-B donor spleen cells.

  Jin MX, Chowdhury NC, James T, Engelstad K, Hardy MA, Oluwole SF. Jin MX, et al. Transplant Proc. 1993 Feb;25(1 Pt 1):291. Transplant Proc. 1993. PMID: 8438304 No abstract available.
• Transplantation tolerance.

  Wood KJ. Wood KJ. Curr Opin Immunol. 1991 Oct;3(5):710-4. doi: 10.1016/0952-7915(91)90101-6. Curr Opin Immunol. 1991. PMID: 1755988 Review.
• Use of donor bone marrow cells for the induction of specific allograft prolongation.

  Gozzo JJ. Gozzo JJ. Surv Immunol Res. 1982;1(2):133-6. doi: 10.1007/BF02918337. Surv Immunol Res. 1982. PMID: 6195712 Review. No abstract available.